主题：【原创】解读港大疫情疫苗有效率数字-对死亡及重病住院不分伯仲 -- 脊梁硬

刚刚。阿根廷128万人数据发表，涉及国药与两种载体疫苗比较

防死亡有效性 85% （84-86%）

国药 85·0% (84·0–86·0) for BBIBP-CorV following two doses.

From Jan 31, to Sept 14, 2021, 1 282 928 individuals were included, of whom 687 167 (53·6%) were in the rAd26-rAd5 analysis, 358 431 (27·6%) in the ChAdOx1 nCoV-19 analysis, and 237 330 (18·5%) in the BBIBP-CorV analysis. Vaccine effectiveness after two doses was high for all three vaccines, adjusted odds ratio 0·36 (95% CI 0·35–0·37) for rAd26-rAd5, 0·32 (0·31–0·33) for ChAdOx1 nCoV-19, and 0·56 (0·55–0·58) for BBIBP-CorV. After two doses, the effect on deaths was higher than that on risk of infection: adjusted hazard ratio 0·19 (95% CI 0·18–0·21) for rAd26-rAd5, 0·20 (0·18–0·22) for ChAdOx1 nCoV-19, and 0·27 (0·25–0·29) for BBIBP-CorV. The indirectly estimated effectiveness on deaths was 93·1% (95% CI 92·6–93·5) for rAd26-rAd5, 93·7% (93·2–94·3) for ChAdOx1 nCoV-19, and

85·0% (84·0–86·0) for BBIBP-CorV following two doses.

Interpretation

The vaccines used in Argentina showed effectiveness in reducing infection and death by SARS-CoV-2 and COVID-19.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00011-3/fulltext